share_log

6-K: Financial Report for the Period 1 January 2024 to 30 June 2024

6-K: Financial Report for the Period 1 January 2024 to 30 June 2024

6-K: 2024年1月1日至2024年6月30日期间的财务报告
美股sec公告 ·  08/07 06:56
Moomoo AI 已提取核心信息
Novo Nordisk A/S, a global healthcare leader in diabetes care, reported a significant increase in sales and operating profit for the first half of 2024. Sales rose by 24% in Danish kroner and 25% at constant exchange rates (CER) to DKK 133.4 billion, while operating profit grew by 18% in Danish kroner and 19% at CER to DKK 57.8 billion. The company's performance was particularly strong in North America, with a 36% increase in sales. Diabetes and Obesity care sales surged by 26% in Danish kroner, driven by GLP-1 diabetes sales growth and Obesity care growing by 37% in Danish kroner. However, rare disease sales saw a decrease. Novo Nordisk also completed the phase 3 FRONTIER 2 trial with Mim8 for haemophilia A and received a positive CHMP opinion for Wegovy in the EU. The company updated its 2024 outlook, expecting sales growth of 22-28% at CER and operating profit growth of 20-28% at CER. The financial report was released on August 7, 2024, alongside an earnings call for investors.
Novo Nordisk A/S, a global healthcare leader in diabetes care, reported a significant increase in sales and operating profit for the first half of 2024. Sales rose by 24% in Danish kroner and 25% at constant exchange rates (CER) to DKK 133.4 billion, while operating profit grew by 18% in Danish kroner and 19% at CER to DKK 57.8 billion. The company's performance was particularly strong in North America, with a 36% increase in sales. Diabetes and Obesity care sales surged by 26% in Danish kroner, driven by GLP-1 diabetes sales growth and Obesity care growing by 37% in Danish kroner. However, rare disease sales saw a decrease. Novo Nordisk also completed the phase 3 FRONTIER 2 trial with Mim8 for haemophilia A and received a positive CHMP opinion for Wegovy in the EU. The company updated its 2024 outlook, expecting sales growth of 22-28% at CER and operating profit growth of 20-28% at CER. The financial report was released on August 7, 2024, alongside an earnings call for investors.
全球医疗保健领导者诺和诺德报告称，2024年上半年销售额和营业利润显着增长。销售额在丹麦克朗上涨24％，在恒定汇率下上涨25％（CER）至1334亿丹麦克朗，而营业利润在丹麦克朗上增长18％，在恒定汇率下上涨19％（CER）至578亿丹麦克朗。该公司在北美市场表现尤为强劲，销售额增长了36％。2型糖尿病和肥胖症护理销售额在丹麦克朗上激增26％，其中GLP-1糖尿病销售增长和肥胖症护理销售增长37％。然而，罕见病的销售出现了下降。诺和诺德还完成了Mim8用于血友病A的第3期FRONTIER 2试验，并获得了Wegovy在欧盟的积极CHMP意见。该公司更新了2024年的前景，预计在CER下销售增长为22-28％，营业利润增长为20-28％。2024年8月7日，公司发布了财务报告，并举行了业绩会。
全球医疗保健领导者诺和诺德报告称，2024年上半年销售额和营业利润显着增长。销售额在丹麦克朗上涨24％，在恒定汇率下上涨25％（CER）至1334亿丹麦克朗，而营业利润在丹麦克朗上增长18％，在恒定汇率下上涨19％（CER）至578亿丹麦克朗。该公司在北美市场表现尤为强劲，销售额增长了36％。2型糖尿病和肥胖症护理销售额在丹麦克朗上激增26％，其中GLP-1糖尿病销售增长和肥胖症护理销售增长37％。然而，罕见病的销售出现了下降。诺和诺德还完成了Mim8用于血友病A的第3期FRONTIER 2试验，并获得了Wegovy在欧盟的积极CHMP意见。该公司更新了2024年的前景，预计在CER下销售增长为22-28％，营业利润增长为20-28％。2024年8月7日，公司发布了财务报告，并举行了业绩会。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息